Item 1.
|
Security and Issuer.
|
This Schedule 13D relates to the shares of common stock, $0.001 par value per share (Common Stock), of Solid Biosciences Inc. (the
Issuer). The address of the principal executive offices of the Issuer is 141 Portland Street, Fifth Floor, Cambridge MA 02139.
Item 2.
|
Identity and Background
|
(a) This Schedule 13D is being filed on behalf of Ultragenyx Pharmaceutical Inc., a Delaware corporation (the Reporting
Person).
(b) The Reporting Persons principal executive offices are located at 60 Leveroni Court, Novato,
California 94949. The directors and executive officers of the Reporting Person and their principal occupations and business addresses are set forth on Schedule I and incorporated by reference into this Item 2.
(c) The principal business of the Reporting Person is as a biopharmaceutical company focused on the identification, acquisition,
development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases.
(d)
During the last five years, neither the Reporting Person nor any Person named on Schedule I has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the last five years, neither the Reporting Person nor any Person named on Schedule I has been a party to a civil
proceeding of a judicial or administrative body of competent jurisdiction resulting in he, she or it being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or
state securities laws or finding any violation with respect to such laws.
Item 3.
|
Source and Amount of Funds or Other Considerations
|
This Schedule 13D relates to the Reporting Persons purchase from the Issuer of 7,825,797 shares (the Shares) of the
Issuers Common Stock on October 22, 2020, at a price of $5.1113 per share, for an aggregate purchase price of $39,999,996.21. The Shares were purchased by the Reporting Person with its working capital.
Item 4.
|
Purpose of Transaction
|
On October 22, 2020 (the Closing Date), the Reporting Person purchased the Shares in a private placement transaction with the
Issuer for an aggregate purchase price of $39,999,996.21, pursuant to a Stock Purchase Agreement dated as of October 22, 2020 (the Stock Purchase Agreement). In connection with the Stock Purchase Agreement, the
Reporting Person entered into an Investor Agreement with the Issuer dated as of October 22, 2020 (the Investor Agreement).
Pursuant to the Investor Agreement, the Reporting Person agreed to certain standstill restrictions until the earlier to occur of (i) 24 months after the
Closing Date or (ii) other specified events. Further, subject to the terms of the Investor Agreement, the Reporting Person is restricted from selling, transferring or otherwise disposing of the Shares without the prior approval of the Issuer
until the earlier of (i) 18 months following the closing date, (ii) the termination of the Collaboration and License Agreement between the Issuer and the Reporting Person dated October 22, 2020 (the Collaboration
Agreement) and (iii) certain other specified events. So long as the Reporting Person holds at least 10% of the Issuers outstanding Common Stock, the Shares will be subject to a voting agreement, such that until the earliest
to occur of certain specified events, and subject to specified conditions, the Reporting Person will, and will cause its permitted transferees to, vote in accordance with the recommendation of the Issuers Board of Directors with respect to
specified matters, and the Reporting Person granted the Issuer an irrevocable proxy with respect to the foregoing, subject to the terms of the Investor Agreement. The Investor Agreement also provides the Reporting Person with certain registration
rights.